JP2005506294A - テガフル、ウラシル、フォリン酸、パクリタキセルおよびカルボプラチンの投与による腫瘍の治療方法および剤形 - Google Patents

テガフル、ウラシル、フォリン酸、パクリタキセルおよびカルボプラチンの投与による腫瘍の治療方法および剤形 Download PDF

Info

Publication number
JP2005506294A
JP2005506294A JP2002574974A JP2002574974A JP2005506294A JP 2005506294 A JP2005506294 A JP 2005506294A JP 2002574974 A JP2002574974 A JP 2002574974A JP 2002574974 A JP2002574974 A JP 2002574974A JP 2005506294 A JP2005506294 A JP 2005506294A
Authority
JP
Japan
Prior art keywords
tegafur
uracil
dose
day
carboplatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002574974A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005506294A5 (enExample
Inventor
ジャファーフセン・エイ・アジャニ
スティーブン・イー・ベナー
テリー・エス・ドゥーガン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2005506294A publication Critical patent/JP2005506294A/ja
Publication of JP2005506294A5 publication Critical patent/JP2005506294A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2002574974A 2001-03-06 2002-03-04 テガフル、ウラシル、フォリン酸、パクリタキセルおよびカルボプラチンの投与による腫瘍の治療方法および剤形 Pending JP2005506294A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27357701P 2001-03-06 2001-03-06
PCT/US2002/006262 WO2002076459A1 (en) 2001-03-06 2002-03-04 Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin

Publications (2)

Publication Number Publication Date
JP2005506294A true JP2005506294A (ja) 2005-03-03
JP2005506294A5 JP2005506294A5 (enExample) 2005-12-22

Family

ID=23044526

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002574974A Pending JP2005506294A (ja) 2001-03-06 2002-03-04 テガフル、ウラシル、フォリン酸、パクリタキセルおよびカルボプラチンの投与による腫瘍の治療方法および剤形

Country Status (20)

Country Link
US (1) US6770653B2 (enExample)
EP (1) EP1368034A1 (enExample)
JP (1) JP2005506294A (enExample)
KR (1) KR20030081496A (enExample)
BR (1) BR0207443A (enExample)
CA (1) CA2439676A1 (enExample)
CZ (1) CZ20032266A3 (enExample)
EE (1) EE200300429A (enExample)
HR (1) HRP20030801A2 (enExample)
HU (1) HUP0303466A3 (enExample)
IL (1) IL157357A0 (enExample)
IS (1) IS6925A (enExample)
MX (1) MXPA03007989A (enExample)
NO (1) NO20033910L (enExample)
PL (1) PL363967A1 (enExample)
RU (1) RU2284184C2 (enExample)
SK (1) SK10602003A3 (enExample)
WO (1) WO2002076459A1 (enExample)
YU (1) YU69903A (enExample)
ZA (1) ZA200306541B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018513185A (ja) * 2015-04-22 2018-05-24 シン−ナット プロダクツ エンタープライズ エルエルシー 共結晶組成物及びその医薬用途

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0115162A (pt) * 2000-11-06 2003-10-21 Pharma Mar Sa Tratamentos antitumorais eficazes
MXPA05009781A (es) 2003-03-14 2005-10-26 Taiho Pharmaceutical Co Ltd Potenciador de efecto antitumoral y agente antitumoral.
WO2004087105A1 (en) * 2003-04-02 2004-10-14 Celator Pharmaceuticals, Inc. Combination formulations of platinum agents and fluoropyrimidines
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
US20080255132A1 (en) * 2003-11-14 2008-10-16 Eric Rowinsky Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
KR20050099311A (ko) * 2004-04-09 2005-10-13 에이엔에이치 케어연구소(주) 주사제용 항암제 조성물
PL1827500T3 (pl) * 2004-10-26 2009-09-30 Pharma Mar Sa Pegylowana liposomalna doksorubicyna w kombinacji z ekteinascydyną 743
DK1658848T3 (da) 2004-10-29 2007-11-26 Pharma Mar Sa Formuleringer omfattende ecteinascidin og et disaccharid
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
SG166775A1 (en) 2005-02-18 2010-12-29 Abraxis Bioscience Llc Combinations and modes of administration of therapeutic agents and combination therapy
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
AU2008202078B2 (en) * 2007-10-10 2012-05-31 Wellkey Holdings Limited Stability of secondary metabolite mass production through synchronized plant cell cultures
AU2008313634A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Prognostic molecular markers for ET-743 treatment
CA2794147A1 (en) 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma
KR101894689B1 (ko) 2010-03-29 2018-09-04 아브락시스 바이오사이언스, 엘엘씨 암의 치료 방법
EP2575804A4 (en) 2010-06-04 2013-10-23 Abraxis Bioscience Llc METHOD FOR THE TREATMENT OF PANCREASCRE
AU2017319260B2 (en) 2016-08-31 2020-01-30 Fujifilm Corporation Anti-tumor agent, anti-tumor effect enhancer, and anti-tumor kit
RU2646450C1 (ru) * 2017-05-11 2018-03-05 Владимир Михайлович Курусин Способ лечения предраковых и ранних стадий раковых заболеваний желудка
WO2019146130A1 (ja) 2018-01-29 2019-08-01 富士フイルム株式会社 胆道がん用抗腫瘍剤および胆道がんの処置方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
US4328229A (en) 1978-03-29 1982-05-04 Taiho Pharmaceutical Company Limited Anti-cancer composition for delivering 5-fluorouracil to cancer tissues
US5534513A (en) 1991-09-05 1996-07-09 Taiho Pharmaceutical Company, Ltd. Antitumor potentiator and antitumor composition
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
RU2194541C1 (ru) * 2001-07-13 2002-12-20 Научно-исследовательский институт онкологии Томского научного центра СО РАН Способ комбинированного лечения больных местнораспространенным раком желудка

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018513185A (ja) * 2015-04-22 2018-05-24 シン−ナット プロダクツ エンタープライズ エルエルシー 共結晶組成物及びその医薬用途

Also Published As

Publication number Publication date
WO2002076459A1 (en) 2002-10-03
SK10602003A3 (en) 2004-10-05
BR0207443A (pt) 2004-04-06
EP1368034A1 (en) 2003-12-10
CZ20032266A3 (cs) 2004-02-18
ZA200306541B (en) 2004-11-22
HRP20030801A2 (en) 2004-08-31
PL363967A1 (en) 2004-11-29
RU2284184C2 (ru) 2006-09-27
MXPA03007989A (es) 2003-12-04
US6770653B2 (en) 2004-08-03
US20020173482A1 (en) 2002-11-21
HUP0303466A3 (en) 2005-02-28
RU2003129527A (ru) 2005-03-10
CA2439676A1 (en) 2002-10-03
YU69903A (sh) 2006-08-17
NO20033910L (no) 2003-10-23
HUP0303466A2 (hu) 2004-01-28
IL157357A0 (en) 2004-02-19
IS6925A (is) 2003-08-22
NO20033910D0 (no) 2003-09-04
EE200300429A (et) 2003-12-15
KR20030081496A (ko) 2003-10-17

Similar Documents

Publication Publication Date Title
JP2005506294A (ja) テガフル、ウラシル、フォリン酸、パクリタキセルおよびカルボプラチンの投与による腫瘍の治療方法および剤形
JP2012525371A (ja) 癌を治療するためのペンタミジンの組み合わせ
JP2003533485A5 (enExample)
EP1201247B1 (en) Treatment of metastatic renal cell carcinoma
JP2007511499A (ja) コンビネーション
CN101687104A (zh) 包括长春氟宁和曲妥单抗的癌症治疗联合疗法
Johnson et al. A less toxic regimen of 5-fluorouracil and high-dose folinic acid for advanced gastrointestinal adenocarcinomas
BG98825A (bg) Използване на креатин фосфат или фосфоенолпирогроздена киселина за лечение на тумори
Kouroussis et al. A dose escalation study of weekly docetaxel in patients with advanced solid tumors
Van Zandwijk et al. Dose-finding studies with carboplatin, ifosfamide, etoposide, and mesna in non-small cell lung cancer.
US6620816B2 (en) Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide
Collier et al. Doxorubicin hydrochloride, cyclophosphamide, and 5-fluorouracil combination in advanced prostate and transitional cell carcinoma
ES2393398T3 (es) Agente reforzante del efecto antitumoral, agente antitumoral y procedimiento de terapia para el cáncer
Smith et al. Evaluation of topotecan in patients with recurrent for metastatic squamous cell carcinoma of the head and neck: A phase II Southwest Oncology Group study
BRPI0717998A2 (pt) Método para administrar um composto antitumor.
US20060264388A1 (en) Method for treating liver cancer by intrahepatic administration of nemorubicin
WO2008135792A1 (en) Pm00104 compound for use in cancer therapy
US20020169141A1 (en) Oral dosage forms for administration of the combination of tegafur, uracil, folinic acid, and irinotecan and method of using the same
Ajani et al. Phase II study of intravenous 6-thioguanine in patients with advanced carcinoma of the pancreas
AU2002245551A1 (en) Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin
Hantel et al. Phase II trial of piroxantrone in gastric carcinoma: A Southwest Oncology Group study
Liauw et al. The use of capecitabine in the combined-modality therapy for rectal cancer
US20060258736A1 (en) Dosing regimen
AU2002338521A1 (en) Method for treating tumors by the administration of tegaf, uracil, folinic acid, and cyclophisphamide
van Kooten et al. Phase II study of induction chemotherapy with gemcitabine (Gemtro®)(G) and cisplatin (C) in patients (pts) with stage IIIA–IIIB non-small cell lung cancer (NSCLC)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080902

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090217